20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
At the moment, there are no better-performing technologies than the one we use (considering the number of analyzed cytokines and the definition). Our technology is able to analyze 8 different cytokines simultaneously by Elisa and it is completely automatized. Each test is replicated to ensure sensitivity and reproducibility. We already developed CYTOBALANCE test to be utilized to feed the development of the proprietary AI, and without new technologies, the future investments will be mainly allocated to the clinical study, which validates the ability of our AI to integrate the CYTOBALANCE results with anamnestic data and the results of the other HELIXAFE tests to profile an individual’s colorectal cancer risk, other than to marketing and sales activities.
